Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: Background: Irritable bowel syndrome with constipation ( IBS ‐ C ) significantly decreases quality of life and the ability to perform daily living activities. Aim: To demonstrate the long‐term safety, tolerability and patient outcomes of lubiprostone in patients with IBS ‐ C . Methods: This extension study enrolled 522 IBS ‐ C patients who had completed one of two randomised phase 3 studies. All enrolled patients received open‐label lubiprostone orally for 36‐weeks (8 mcg, twice daily). The primary objective was the assessment of long‐term safety and tolerability, monitored via adverse events ( AE s), laboratory parameters and vital signs. Additional outcome endpoints included monthly responder rates and patient evaluations of IBS ‐ C symptom severity and impact on quality of life. Results: The evaluable safety population comprised of 520 patients; 476 of which had patient reported outcome data available. The overall safety profile of lubiprostone during this study was similar to that observed in the preceding phase 3 studies. The most common AE s were diarrhoea (11.0%), nausea (11.0%), urinary tract infection (9.0%), sinusitis (9.0%) and abdominal distention (5.8%). Diarrhoea and nausea were the most common treatment‐related AE s. No serious AE s were considered treatment‐related. Seventeen patients discontinued due to a treatment‐related AE , of which diarrhoea and nausea accounted for six (1.2%) and three (0.6%) respectively. For responder rates and patient‐evaluated parameters ( n = 476), all groups experienced significant improvements from baseline, with initial improvements maintained throughout the study. Conclusion: In patients with irritable bowel syndrome with constipation, lubiprostone 8 mcg twice daily was found to be safe and well tolerated over 9–13 months of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Self-citationPatrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761
Self-citationAn Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., Jia, H., & Bangdiwala, S. I. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01941.x · Cited by 424
Self-citationDROSSMAN, D. A., CHEY, W. D., JOHANSON, J. F., FASS, R., SCOTT, C., PANAS, R., & UENO, R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03881.x · Cited by 399 · cited 2×
“14 Two clinical trials recently assessed the efficacy of lubiprostone for the treatment of IBS-C in adults.(8) The combined results from these two phase 3 trials provide support for the efficacy of lubiprostone in the treatment of the global and individual symptoms experienced by patients with IBS-C.”
BackgroundResultSelf-citationCamilleri, M., Bharucha, A. E., Ueno, R., Burton, D., Thomforde, G. M., Baxter, K., McKinzie, S., & Zinsmeister, A. R. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00264.2005 · Cited by 253
Self-citation
Cited by
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citationACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
Self-citationCamilleri, M., Ford, A. C., Mawe, G. M., Dinning, P. G., Rao, S. S., Chey, W. D., Simrén, M., Lembo, A., Young-Fadok, T. M., & Chang, L. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.95 · Cited by 411
Self-citationDiagnosis and Treatment of Irritable Bowel Syndrome: A Review
Camilleri, M. (2021) · JAMA · doi:10.1001/jama.2020.22532 · Cited by 362
Chang, L., Sultan, S., Lembo, A., Verne, G. N., Smalley, W., & Heidelbaugh, J. J. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.04.016 · Cited by 163
Metadata
- Authors
- Chey, W. D., Drossman, D. A., Johanson, J. F., Scott, C., Panas, R. M., & Ueno, R.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2012-01-18
- Volume
- 35
- Issue
- 5
- Pages
- 587-599
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2011319006
- Cited by
- 121
- References
- 6
- FWCI
- 15.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. https://app.cochat.ai/papers/10.1111/j.1365-2036.2011.04983.x
- The paper
- Chey, W. D., Drossman, D. A., Johanson, J. F., Scott, C., Panas, R. M., & Ueno, R. (2012). Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2011.04983.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.